

ORIGINAL ARTICLE

Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Vikas S. Sridhar*, Luxcia Kugathasan¹, Yuliya Lytvyn², Yangqing Deng, Hongyan Liu³, Leif Erik Lovblom, Josephine Tse, Massimo Nardone⁴, John S. Floras⁵, Tosin Osuntokun, Tomoyuki Tobushi⁶, Ruthabella C.Y. Lam, Brian Lam, Jasper Stevens⁷, Dylan Burger⁸, Daan J. Touw⁹, Hiddo J.L. Heerspink¹⁰, Julie A. Lovshin, Bruce A. Perkins¹¹, David Z.I. Cherney¹²

BACKGROUND: We investigated the impact of 12 weeks of sodium-glucose cotransporter-2 inhibition (dapagliflozin 10 mg daily) on vascular stiffness, cardiac and kidney function, and neurohormonal pathways in participants at cardiovascular risk.

METHODS: This randomized double-blind, parallel-group, placebo-controlled study enrolled 51 participants with at least 1 established cardiovascular condition or cardiovascular risk factor. Participants underwent 3 sequential assessments under clamped euglycemia (4–6 mmol/L): at baseline, at 1 week and 12 weeks of treatment. The primary outcome was vascular arterial stiffness, quantified as augmentation index and pulse-wave velocity. Secondary outcomes included: blood pressure, body fluid composition, noninvasive cardiac output monitoring, arterial vasodilatation tests, heart rate variability, echocardiography, iothexol-measured glomerular filtration rate, and natriuresis.

RESULTS: Dapagliflozin decreased vascular arterial stiffness, as measured by aortic augmentation index (placebo-adjusted change of $-7.4 \pm 2.8\%$, $P=0.01$) after 12 weeks. Dapagliflozin acutely decreased extracellular fluid (-0.8 ± 0.3 L, $P=0.004$), with sustained reductions in thoracic fluid content at 12 weeks (-3.3 ± 1.5 kΩ⁻¹, $P=0.03$). Reductions in measured glomerular filtration rate (-5.8 ± 2.1 mL/min per 1.73m², $P=0.008$) were accompanied by acute increases in proximal sodium excretion ($5.1 \pm 2.2\%$, $P=0.03$), absolute fractional distal sodium reabsorption ($4.4 \pm 2.1\%$, $P=0.04$), and urine adenosine (0.21 ± 0.08 mmol/L per μmol Cr, $P=0.01$).

CONCLUSIONS: Dapagliflozin induced early cardiorenal changes in individuals at varying levels of cardiovascular risk in whom evidence of clinical protection is lacking. Clinical trials in lower-risk populations, particularly in the context of primary prevention, are needed to determine whether these effects of sodium-glucose cotransporter-2 inhibition translate into improved clinical cardiorenal outcomes.

REGISTRATION: URL: <https://www.clinicaltrials.gov>; Unique identifier: NCT04258371. (*Hypertension*. 2026;83:432–447. DOI: 10.1161/HYPERTENSIONAHA.125.25955.) • **Supplement Material.**

Key Words: glomerular filtration rate ■ heart disease risk factors ■ sodium ■ sodium-glucose transporter 2 inhibitors ■ vascular stiffness

Cardiovascular disease remains a leading global cause of morbidity and mortality^{1,2} and shares a strong bidirectional relationship with kidney disease.

Specifically, patients with cardiovascular disease are at 2- to 4-fold greater risk of chronic kidney disease (CKD).³ Similarly, patients with CKD are at increased

Correspondence to: David Z.I. Cherney, MD, PhD, Toronto General Hospital, 585 University Ave, 8N-845, Toronto, Ontario, M5G 2N2, Canada. Email david.cherney@uhn.ca

*V.S. Sridhar and L. Kugathasan contributed equally.

Supplemental Material is available at <https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.125.25955>.

For Sources of Funding and Disclosures, see page 445.

© 2025 American Heart Association, Inc.

Hypertension is available at www.ahajournals.org/journal/hyp

NOVELTY AND RELEVANCE

What Is New?

This study shows that dapagliflozin improves early cardiovascular and kidney health markers after 12 weeks in patients at varying cardiovascular risk, with or without type 2 diabetes.

What Is Relevant?

These improvements were seen in people who would not typically qualify for SGLT2 (sodium-glucose cotransporter-2) inhibitors under current guidelines. This suggests potential benefits for a wider group of patients.

Clinical/Pathophysiological Implications?

Early use of SGLT2 inhibitors may help prevent cardiovascular and kidney disease in at-risk individuals. These findings highlight the need for larger trials to assess whether earlier intervention can improve outcomes, even in those without diabetes/cardiovascular disease.

Nonstandard Abbreviations and Acronyms	
ACE	angiotensin-converting enzyme
AIx	augmentation index
ANP	atrial natriuretic peptide
ASCVD	atherosclerotic cardiovascular disease
BNP	B-type natriuretic peptide
CKD	chronic kidney disease
E/e′	left ventricular filling pressures/diastolic function
FELi	fractional excretion of lithium
FE_{Na}	fractional excretion of sodium
FMD	flow-mediated dilatation
GFR	glomerular filtration rate
PWV	pulse wave velocity
RAAS	renin-angiotensin-aldosterone system
SGLT2	sodium-glucose cotransporter 2
T2D	type 2 diabetes
TGF	tubuloglomerular feedback

risk of cardiovascular events.^{4,5} SGLT2 (sodium-glucose cotransporter-2) inhibitors are highly effective in lowering adverse cardiovascular and kidney outcomes,^{6,7} and are currently recommended in patients with type 2 diabetes (T2D) with or at high risk for atherosclerotic cardiovascular disease (ASCVD),⁸ and in patients with heart failure and CKD regardless of T2D status.^{9,10}

However, less is known about the efficacy of SGLT2 inhibition in patients with cardiovascular risk factors who do not yet meet criteria for indication, particularly in the context of primary prevention of cardiovascular and kidney events. This includes at-risk patients with estimated glomerular filtration rate (GFR) >45 mL/min per 1.73m², without albuminuria or heart failure, as well as patients with T2D without ASCVD or at high ASCVD risk. Analyses of kidney outcome studies demonstrate that treatment with SGLT2 inhibition

earlier in the course of kidney disease is associated with a greater time to dialysis initiation.¹¹ Given the bidirectional association between cardiovascular and kidney risk, this highlights a potentially important gap in current treatment guidelines: individuals with cardiovascular risk factors who do not yet meet formal indications for SGLT2 inhibitor therapy may still benefit from early initiation, potentially achieving similar reductions in future cardiovascular and kidney events as those already eligible for treatment.

A large body of work has demonstrated clinical cardiovascular and kidney protection with SGLT2 inhibition. These benefits are consistent across subgroups with and without T2D, and independent of baseline glycated hemoglobin or glycated hemoglobin reductions after therapy.^{12,13} Several mechanisms have been proposed to underlie the cardiovascular and kidney protective effects of SGLT2 inhibition. Among these are reductions in arterial stiffness, natriuresis, lowering of glomerular pressure, and improvements in kidney metabolic perturbations, though this has mostly been limited to cohorts with diabetes.^{14–17} To date, no human studies have used an integrative approach to better understand the incremental effect of SGLT2 inhibitors on the cardiokidney-metabolic axis across the cardiovascular risk strata, including both patients with and without diabetes and beyond those currently meeting indication criteria. Moreover, in the absence of outcome data in lower-risk groups, mechanistic studies may offer insight in how these therapies could translate to novel patient populations in the future.

In the present trial, our aim was to understand the effects of SGLT2 inhibition on vascular stiffness, cardiac and kidney function, natriuresis, and neurohormonal pathways in participants at increased cardiovascular risk with or without T2D. The primary objective was to determine if dapagliflozin modifies arterial stiffness, a surrogate marker of cardiovascular risk after 12 weeks of treatment. Arterial stiffness captures the cumulative effects of hemodynamic and metabolic stress on the vasculature and serves as a validated surrogate marker of cardiovascular

risk, independently predicting future events in individuals without established end-organ disease.^{18–22} Secondary objectives assessed the mechanisms associated with cardio-kidney protection, incorporating comprehensive measurements of cardiac structure and function, tubular sodium handling, volume status, and metabolic health.

METHODS

Data Availability

The data supporting the findings of this study are available from the corresponding author (D.Z.I.C.) on reasonable request.

Study Participants

A detailed list of study inclusion and exclusion criteria assessed at screening is reported in [Table S1](#). Briefly, the inclusion criteria were as follows: patients at increased cardiovascular risk, with an estimated GFR ($\text{GFR}_{\text{CKD-EPI}(2021)}$) ≥ 30 mL/min per 1.73m^2 , average seated blood pressure $\leq 160/100$ at screening, glycated hemoglobin $< 12.0\%$ for patients with T2D, on a stable dose of a maximally tolerated ACE (angiotensin-converting enzyme) inhibitor, angiotensin receptor blocker, or renin inhibitor for ≥ 30 days before screening, on a stable diuretic dose for ≥ 14 days before baseline visit. Increased cardiovascular risk was defined as patients ≥ 50 years of age with ≥ 1 cardiovascular coexisting condition (coronary heart disease, cerebrovascular disease, peripheral vascular disease, CKD $\geq \text{G3}$, or chronic heart failure of New York Heart Association class II or III) or patients ≥ 60 years of age with ≥ 1 cardiovascular risk factor (microalbuminuria, hypertension and left ventricular hypertrophy, left ventricular systolic or diastolic dysfunction, or an ankle-brachial index < 0.9). The local Research Ethics Board at the University Health Network (Toronto, Canada) approved the protocol and study participants gave informed consent before study procedures. The study was conducted according to the International Conference on Harmonization on Good Clinical Practice.

Study Design

This single-center, double-blind, placebo-controlled, parallel-group clinical trial was registered on January 23, 2020, with a study protocol and statistical analysis plan. Subjects at Toronto General Hospital, Canada, who passed screening completed baseline physiological assessments before undergoing 1:1 randomization to receive either 10 mg oral dapagliflozin once daily or a matched placebo. A computer-generated randomized code generated by an independent University Health Network biostatistician was sent directly to the pharmacy to maintain blinding of the study coordinators involved with consenting and enrolling, investigators and participants. Study medication was initiated the morning after the baseline visit, and participants returned for identical assessments at acute (week 1) and chronic (week 12) follow-up visits ([Figure S1](#)). These time points were selected to evaluate whether proximal tubular natriuresis induces an early, tubuloglomerular feedback (TGF)-mediated reduction in GFR at week 1,^{14,23,24} followed by a return toward baseline by Week 12, reflecting renal function stability as observed in clinical trials. Study drug and a matching placebo were provided by AstraZeneca.

The primary outcome of this study was the change in arterial stiffness after 12 weeks of dapagliflozin treatment, assessed

as a marker of vascular health and nitric oxide availability. Both short-term (1 week) and longer-term (12 weeks) effects were measured. Secondary outcomes included changes in vascular and systemic function, such as flow-mediated dilation, blood pressure (seated and supine), stroke volume, echocardiography-derived cardiac output and volume markers derived from bioimpedance spectroscopy. The study also evaluated hormone responses related to fluid balance, including natriuretic peptides and components of the renin-angiotensin-aldosterone system (RAAS). Effects on kidney function were assessed through measures of sodium handling, iothexol-measured GFR and urine adenosine.

Physiological assessments at baseline, Week 1 and Week 12 of therapy were performed during controlled clamped euglycemic conditions ($4\text{--}6$ mmol/L),²⁵ to minimize confounding influences of neurohumoral activation secondary to hyperglycemia.^{25,26} A peripheral venous cannula was inserted into the left arm to facilitate the infusion of glucose and insulin. Blood glucose levels were measured using a glucose meter. If glucose values were outside the target euglycemic range of 4.0 to 6.0 mmol/L, insulin was administered at a dose calculated per kilogram of body weight or intravenous/oral dextrose was provided as appropriate. Blood glucose was subsequently monitored and adjusted with insulin or dextrose every 15 to 30 minutes until euglycemia was achieved. Once within the target range, glucose measurements were performed every 30 to 60 minutes to ensure maintenance of stable euglycemia throughout the clamp procedure.

Participants were instructed to adhere to a high-sodium (> 150 mmol/d), moderate protein diet (< 1.5 g/kg/d) for 7 days leading up to each of the 3 visits to ensure volume repletion and to avoid the confounding hyperfiltration effect attributable to high protein intake.²⁷ Participants were asked to avoid alcohol and tobacco for ≥ 72 hours and fast overnight ≥ 12 hours before all 3 visits. All measures except sitting blood pressure were captured in the supine position.

Plasma and Urine Sample Collection and Molecular Profiling

Participants collected 24-hour urine 1 day before the physiological assessment visit. On arrival and before euglycemic clamping, safety blood work, spot urine, weight and waist circumference were collected using standard laboratory methods. Glycated hemoglobin was measured by high-performance liquid chromatography.

After the euglycemic clamp was achieved but before iothexol infusion, baseline plasma, serum and urine samples were collected. Baseline plasma samples were profiled for RAAS and volume markers, including angiotensin II, aldosterone, plasma renin concentration, ACE protein, plasma renin activity, BNP (B-type natriuretic peptide), and ANP (atrial natriuretic peptide), norepinephrine, epinephrine, and urine adenosine.^{14,28–31} Analytic methods are described in [Supplemental Methods](#).

Measurement of Kidney Function at Each Physiological Assessment Visit

GFR was measured at euglycemia in the supine position by infusing iothexol (1500 mg Omnipaque) over 2 minutes through a third intravenous line, as described previously.¹⁴ After 120

minutes of equilibration, blood samples were collected every 30 minutes up to 240 minutes postiohexol infusion. Plasma iohexol concentrations were measured³² and extrapolated for the clearance curve.³³

Tubular sodium handling was measured using established sodium and lithium clearance techniques^{34,35}. At 22:00 hours on the night before the assessments (weeks 0, 1, and 12), all participants took 300 mg of oral lithium carbonate (Li^+CO_3) to derive renal segmental tubular Na^+/Li^+ clearance measurements the following day. Blood and urine samples were obtained at 10:00h the day of the visit after clamped euglycemic conditions were achieved to measure distal and proximal tubular sodium handling. Fractional excretion of sodium (FE_{Na}), fractional excretion of lithium (FE_{Li}), and absolute distal sodium reabsorption rate ($\text{FE}_{\text{Li}} - \text{FE}_{\text{Na}}$) were calculated using conventional formula described previously.³⁶

Measurement of Hemodynamic and Metabolic Function at Each Physiological Assessment Visit

Arterial stiffness was captured (SPC-301, Millar Instruments SphygmoCor, AtCor Medical Systems Inc., Sydney, Australia) using a high-fidelity micromanometer. The right radial and carotid artery waveforms were recorded to generate corresponding central aortic pressure waveform data. The difference between the second systolic peak and inflection point was expressed as a percentage of the central pulse pressure, indexed to a 75 bpm average heart rate, and reported as aortic augmentation index (AIx).^{20–22} Carotid-femoral pulse-wave velocity (PWV) was measured by consecutive recordings of the ECG-gated right carotid and femoral artery waveform.³⁷ Two time domain indices of heart rate variability were also recorded for 10 minutes: root mean square successive difference and SD of normal-to-normal interval. Measurements were taken twice, and averaged.

Blood pressure was captured using 2 monitoring systems. First, an automated sphygmomanometer (DINAMAP sphygmomanometer, Critikon, FL) was used to measure seated mean arterial pressure, systolic and diastolic blood pressure, and heart rate over the right brachial artery. Second, a non-invasive cardiac output monitoring device (Cheetah Medical, Newton Center, MA, FL) was used to capture 3 consecutive blood pressure and cardiac measures (ie, cardiac output, stroke volume, systemic vascular resistance, thoracic fluid content) using ECG-based bioimpedance.³⁸ Measurements were replicated and averaged.

Echocardiography, using the General Electric's Vivid 7 and E9 (GE, 7–15 MHz linear array transducer, General Electric Corp, Wauwatosa, WI) ultrasound system, transthoracic 2-dimensional images, was also performed with endocardial border definition.³⁹ Detailed echocardiography procedure is provided in the [Supplemental Methods](#).

Flow-mediated dilatation (FMD) was quantified, as per our previous work^{40–43} using vascular ultrasonography (Vividi, 7–15 MHz linear array transducer; GE/Vingmed, Waukesha, WI, FL) as the percent change in peak vessel diameter in response to pneumatic cuff placed distal of the antecubital fossa (cuff inflation for 5 minutes at 200 mmHg followed by deflation) and 400 μg of sublingual glyceryl trinitrate spray. Detailed FMD procedure is provided in the [Supplemental Methods](#).

Body composition was measured noninvasively using bio-impedance spectroscopy analysis under clamped euglycemic conditions, as described elsewhere.⁴⁴ Variables captured included extracellular fluid, total body water, fat mass, and fat-free mass. Plasma volume was estimated using the Strauss equation.^{45,46}

Statistical Analysis

The primary end point of this study was the change from baseline in arterial stiffness after treatment with dapagliflozin 10 mg once daily for 12 weeks compared with placebo, defined by the difference in carotid-femoral PWV during stable euglycemic conditions. The planned sample size was based on the primary arterial stiffness end point: with an expected mean baseline carotid-femoral PWV of 7.5 m/s and an SD of the change in carotid-femoral PWV of 0.8 m/s, the expected 12-week change in carotid-femoral PWV was 0.75 m/s for the SGLT2 inhibitor group (compared with the expected change of 0 m/s in the placebo group).⁴⁷ Using a sample size calculation based on a 2-sample Student *t* test assuming an alpha-level of 0.05 and 90% power, this required 25 patients per group, for a total sample size of 50 participants.

Both acute and chronic effects of therapy were evaluated on all randomized participants, thereby repeating analysis at week 1 and week 12. Linear mixed-effects models were employed to assess the primary and secondary end points with terms for treatment group, visit, and the treatment-by-visit interaction. The vector of outcomes to assess the effect of dapagliflozin incorporated the baseline outcome value. We assumed a compound symmetry covariance structure with an intention-to-treat analysis and defined participant-level random intercept to account for repeated measures within subjects. The analyses implemented a missing-at-random framework with a restricted-maximum-likelihood approach for estimation. Diagnostics plots based on the marginal and conditional residuals were assessed for overall fit. Placebo-adjusted values were defined as the difference in mean change from baseline between the dapagliflozin and placebo groups, corresponding to the treatment-by-time interaction term in the mixed-effects model. These values represent the estimated additional effect attributable to dapagliflozin compared with placebo. Subgroup analysis was performed using a 3-way interaction model incorporating treatment, visit, and diabetes. Significant tests were 2-sided and $\alpha=0.05$. Nominal *P* values are reported for the secondary outcomes. Secondary outcomes were exploratory in nature and hypothesis-generating and therefore were not corrected for multiple comparisons. Frequency of adverse events, non-adherence, and drug discontinuation was tabulated. Data were analyzed using R Statistical Software (v4.4.1; R Core Team 2024).

RESULTS

Baseline Characteristics

Of the 65 individuals screened between February 2020 and 2024, 51 were enrolled and randomized to either dapagliflozin ($n=26$) or placebo ($n=25$). All 51 participants completed the study, with the primary end point

of arterial stiffness evaluated (Figure S2). Baseline characteristics are presented in the Table. At randomization, 71% of participants were male, with a mean age of 67 ± 9 years, body mass index of 30 ± 7 kg/m², estimated GFR_{CKD-EPI(2021)} of 76 ± 20 mL/min per 1.73 m², systolic blood pressure of 128 ± 16 mm Hg and a median urine albumin-to-creatinine ratio of 1.7 (0.7–3.2) mg/mmol.

The majority of participants (59%) were receiving statin therapy, 37% were prescribed an ACE inhibitor, 43% an angiotensin receptor blocker, and 35% a diuretic. Diuretic and RAAS inhibitor doses remained consistent throughout the treatment period. 24 participants (47%) had T2D with similar baseline characteristics to those without T2D (Table S2).

Table. Baseline Demographic and Clinical Characteristics at Randomization

	Overall (N=51)	Dapagliflozin (n=26)	Placebo (n=25)
Male	36 (71)	17 (65)	19 (75)
Age, y	67.0±9.1	65.9±8.5	68.1±9.7
Race and ethnicity			
White	29 (57)	18 (69)	11 (44)
Black	7 (14)	2 (8)	5 (20)
Asian	11 (22)	3 (12)	8 (32)
Hispanic	1 (2)	1 (4)	0 (0)
Other	3 (6)	2 (8)	1 (4)
BMI, kg/m ²	30.1±6.9	29.4±8.6	30.8±4.6
HbA1c,* %	6.3±0.9	6.4±1.1	6.2±0.7
Hemoglobin, g/L	131.5±16.1	130.3±19.8	132.8±11.2
Glucose, mmol/L	5.5±1.6	5.7±1.9	5.3±1.2
SBP, mm Hg	127.7±15.6	129.6±14.9	125.7±16.4
DBP, mm Hg	74.6±7.6	73.7±6.3	75.6±8.8
HR, bpm	69.3±12.8	67.9±12.4	70.8±13.2
MAP, mm Hg	92.6±8.8	92.4±7.6	92.7±10.0
24-hour UACR, mg/mmol	1.7 (0.7, 3.2)	1.9 (1.2, 4.2)	1.0 (0.0, 2.6)
eGFR, mL/min per 1.73 m ²	76.4±20.0	75.2±23.4	77.7±16.1
≥90	17 (33)	10 (38)	7 (28)
≥60–<90	19 (37)	4 (15)	15 (60)
≥45–<60	13 (25)	11 (42)	2 (8)
≥30–<45	2 (4)	1 (4)	1 (4)
Concomitant medication			
ACE inhibitor	19 (37)	12 (46)	7 (28)
ARB	22 (43)	8 (31)	14 (56)
Diuretic	18 (35)	11 (42)	7 (28)
Statin	30 (59)	17 (65)	13 (52)
Medical history			
Atrial fibrillation	10 (20)	6 (23)	4 (16)
CKD	8 (16)	3 (12)	5 (20)
Coronary artery disease	3 (6)	3 (12)	0 (0)
T2D	24 (47)	14 (54)	10 (40)
Dyslipidemia	19 (37)	11 (42)	8 (32)
Heart failure	15 (29)	9 (35)	6 (24)
Hypertension	30 (59)	13 (50)	17 (68)
Peripheral artery disease	1 (2)	1 (4)	0 (0)
Stroke	11 (22)	7 (27)	4 (16)

Values are n (%) or mean±SD. UACR reported as median (min, max). eGFR was estimated with the Chronic Kidney Disease Epidemiology Collaboration formula (2021). ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI indicates body mass index; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin A1c; HR, heart rate; MAP, mean arterial pressure; SBP, systolic blood pressure; T2D, type 2 diabetes; and UACR, urine albumin-to-creatinine ratio.

*Measured at screening not randomization.

Effects of Dapagliflozin on Arterial Stiffness

Dapagliflozin decreased aortic Alx at 12 weeks (placebo-adjusted mean \pm SE change of $-7.4\pm 2.8\%$, $P=0.01$), with no significant effect observed acutely from baseline to 1 week ($-2.9\pm 2.6\%$, $P=0.27$; Figure 1; Table S3). Carotid-femoral PWV remained unchanged at 1 week (-0.81 ± 0.86 m/s, $P=0.35$) and 12 weeks (0.46 ± 0.81 m/s, $P=0.57$).

Effects of Dapagliflozin on Hemodynamic and Cardiovascular Parameters

Dapagliflozin did not change blood pressure at 1 week or 12 weeks (Figure 2). Stroke volume, cardiac output

and total peripheral resistance did not change with dapagliflozin at 1 week or 12 weeks (Table S4).

Dapagliflozin decreased left ventricular internal diameter at diastole (-0.29 ± 0.08 cm) and systole (-0.26 ± 0.1 cm), indexed left ventricular mass (-10.94 ± 4.88 g/m²) and left ventricular filling pressures/diastolic function (dividing early diastolic mitral inflow velocity by the early diastolic mitral annular velocity [E/e']) (-1.6 ± 0.7) at 1 week ($P\leq 0.03$ for each comparison). This reduction in left ventricular mass persisted in a sensitivity analysis that excluded participants with atrial fibrillation. However, none of these changes remained statistically significant at 12 weeks (Table S5). No other changes in echocardiographic measures were observed after 1 week or 12 weeks of dapagliflozin (Table S5).

Effects of Dapagliflozin on Kidney Tubular Handling

Total glucose excretion was significantly increased in the dapagliflozin group compared with placebo by 199 ± 27 mmol/d ($P<0.001$) after 1 week, and levels were sustained after 12 weeks of treatment ($P<0.001$; Table S6).

Dapagliflozin increased proximal sodium excretion from baseline after 1 week of treatment, as measured by the change in exogenous lithium clearance, compared with placebo (placebo-adjusted FE_{Li} : $\Delta 5.1\pm 2.2\%$, $P=0.03$; Figure 3). Dapagliflozin also acutely increased absolute fractional distal sodium reabsorption ($FE_{Na}-FE_{Li}$) compared with placebo ($4.4\pm 2.1\%$, $P=0.04$). After 12 weeks of treatment, the placebo-adjusted changes in FE_{Li} ($P=0.31$) and distal sodium handling ($P=0.35$) did not persist (Table S7). There was no effect of dapagliflozin compared with placebo on FE_{Na} from baseline to 1 week or 12 weeks. Acute proximal natriuresis was accompanied by an acute increase in 24-hour urine volume with dapagliflozin compared with placebo ($P=0.04$), but this effect was no longer significant at 12 weeks (Table S7).

The placebo-adjusted increase in urine adenosine was significant with dapagliflozin from baseline to 1 week of treatment ($P=0.01$; Table S8).

Effects of Dapagliflozin on Kidney Function

Compared with placebo, dapagliflozin decreased iothexol-measured GFR by 4.8 ± 1.7 mL/min per 1.73m^2 ($P=0.006$) from baseline to 1 week (Figure 4). Specifically, dapagliflozin decreased measured GFR by 5.5 ± 1.2 mL/min per 1.73m^2 (within-group: $60\pm 3-54\pm 3$ mL/min per 1.73m^2 ; $P_{\text{within group}} < 0.001$; Table S9). This acute dip in measured GFR was mirrored by the placebo-adjusted acute dip in estimated GFR by 4.8 ± 2.0 mL/min per 1.73m^2 ($P=0.02$). The reduction




Figure 1. Changes in arterial stiffness measures after 1 week and 12 weeks of treatment.

Changes in (A) aortic augmentation index (Alx) and (B) carotid-femoral pulse-wave velocity (PWV) are reported after week 1 and week 12 of dapagliflozin treatment or placebo, subtracted from baseline values in patients at cardiovascular risk. P values displayed at the top of the figure correspond to between-group comparisons. All other P values represent within-group comparisons. A linear mixed-effects model was used to analyze end points, incorporating treatment group, visit, and treatment-by-visit interaction as fixed effects, with a patient-level intercept included as a random effect to account for within-subject correlation. Two-sided significance tests were conducted with $\alpha=0.05$, and nominal P values were reported.




Figure 2. Changes in seated blood pressure and supine noninvasive cardiac output monitoring (NICOM) measures after 1 week and 12 weeks of treatment.

Changes in (A) clinical measure of systolic blood pressure (SBP), (B) clinical measure of mean arterial pressure (MAP), and (C) thoracic fluid content (TFC) by NICOM are reported after week 1 and week 12 of dapagliflozin treatment or placebo, subtracted from baseline values. *P* values displayed at the top of the figure correspond to between-group comparisons. All other *P* values represent within-group comparisons. A linear mixed-effects model was used to analyze end points, incorporating treatment group, visit, and treatment-by-visit interaction as fixed effects, with a patient-level intercept included as a random effect to account for within-subject correlation. Two-sided significance tests were conducted with $\alpha=0.05$, and nominal *P* values were reported.

in measured GFR was sustained with dapagliflozin treatment compared with placebo (5.8 ± 2.1 mL/min per 1.73m^2 , $P=0.008$). Placebo-corrected changes in

urine albumin-to-creatinine ratio from spot collection and protein excretion measured using 24-hour urine were not significant (Table S9).




Figure 3. Acute and chronic changes in kidney tubular handling after 1 week and 12 weeks of treatment.

Changes in (A) 24-hour urine glucose, (B) fractional excretion of lithium (FE_{Li}), (C) fractional excretion of sodium (FE_{Na}), (D) distal sodium handling ($FE_{Li} - FE_{Na}$) and (E) urine adenosine normalized to creatinine, are reported after week 1 and week 12 of dapagliflozin treatment or placebo subtracted from baseline values in patients at cardiovascular risk. P values displayed at the top of the figure correspond to between-group comparisons. All other P values represent within-group comparisons. A linear mixed-effects model was used to analyze end points, incorporating treatment group, visit, and treatment-by-visit interaction as fixed effects, with a patient-level intercept included as a random effect to account for within-subject correlation. Two-sided significance tests were conducted with $\alpha = 0.05$, and nominal P values were reported.

Relationship Between Glucose Excretion, Natriuresis and GFR

Among participants treated with dapagliflozin, acute and chronic changes in total glucose excretion were not associated with changes in proximal natriuresis (Figure S3A). Changes in proximal natriuresis were not associated with the changes to iothexol-measured GFR after dapagliflozin therapy (Figure S3B).

Effects of Dapagliflozin on Plasma Volume and Body Composition

Compared with placebo, dapagliflozin treatment decreased body mass index by $0.3 \pm 0.2 \text{ kg/m}^2$ ($P=0.04$) at 1 week, but this was not sustained after 12 weeks. The initial reduction in weight with dapagliflozin by $1.0 \pm 0.4 \text{ kg}$ ($P=0.02$) was sustained after chronic treatment ($-1.3 \pm 0.5 \text{ kg}$, $P_{\text{within group}}=0.01$), but was not significantly different compared with placebo (Figure 5). Acute dapagliflozin treatment decreased total body water compared with placebo by $1.6 \pm 0.8 \text{ L}$ ($P=0.046$; Table S10). These acute reductions in fluid content were accompanied by a placebo-adjusted reduction in fat-free mass by $2.2 \pm 1.0 \text{ kg}$ ($P=0.05$) and extracellular fluid by $0.8 \pm 0.3 \text{ L}$ ($P=0.004$) after 1 week of treatment. These reductions were not sustained after 12 weeks of treatment (Figure 5). Compared with placebo, 12 weeks of dapagliflozin treatment significantly decreased estimated plasma volume by $5.6 \pm 2.4\%$ ($P=0.02$). Fat mass did not change with dapagliflozin after 1 or 12 weeks of treatment (Table S10). Acute placebo-adjusted reductions of $2.8 \pm 1.3 \text{ l/k}\Omega$ ($P=0.04$) in supine thoracic fluid content were observed with dapagliflozin compared with placebo during noninvasive cardiac output monitoring. The placebo-adjusted reductions in supine thoracic fluid content with dapagliflozin were still persistent after 12 weeks ($-3.3 \pm 1.5 \text{ l/k}\Omega$, $P=0.03$).

Effects of Dapagliflozin on Flow-Mediated and Glyceryl Trinitrate-Dependent Dilatation

Compared with placebo, dapagliflozin treatment was not associated with a relative change in peak instantaneous flow after cuff deflation ($P=0.46$; Table S11). Other measures of endothelial-dependent and endothelial-independent vascular function did not change (Table S11).

Effects of Dapagliflozin on Neurohormonal Variables and Heart Rate Variation

Compared with placebo, dapagliflozin increased plasma levels of aldosterone ($103.2 \pm 31.2 \text{ pmol/L}$), renin ($111.9 \pm 48.5 \text{ ng/L}$), and plasma renin activity ($6.0 \pm 2.4 \text{ ng/mL per hour}$) at 1, but not at 12 weeks. Placebo-corrected increases in plasma angiotensinogen were




Figure 4. Changes in glomerular filtration rate after 1 week and 12 weeks of treatment.

Changes in (A) iothexol-measured glomerular filtration rate (GFR) and (B) estimated GFR by the Chronic Kidney Disease Epidemiology Collaboration 2021 equation are reported after week 1 and week 12 of dapagliflozin treatment or placebo, subtracted from baseline values in patients at cardiovascular risk. P values displayed at the top of the figure correspond to between-group comparisons. All other P values represent within-group comparisons. A linear mixed-effects model was used to analyze end points, incorporating treatment group, visit, and treatment-by-visit interaction as fixed effects, with a patient-level intercept included as a random effect to account for within-subject correlation. Two-sided significance tests were conducted with $\alpha=0.05$, and nominal P values were reported.

only significant at 12 weeks. Urine ACE2 activity acutely increased by $76.9 \pm 12.0 \text{ }\mu\text{g}/\mu\text{mol Cr}$ ($P<0.001$); this increase was sustained at 12 weeks (Table S8). Placebo-corrected increases in urine angiotensin II levels were only significant acutely ($P=0.005$).

Dapagliflozin did not change urinary levels of other neurohormones or natriuretic modulators. Plasma nor-epinephrine and epinephrine concentrations did not differ significantly between those allocated dapagliflozin or placebo, at either 1- or the 12-week session; nor did heart rate, root mean square successive difference or SD of normal-to-normal interval (Table S4; Table S8).




Figure 5. Changes in fluid volume and body composition after 1 week and 12 weeks of treatment.

Changes in (A) body mass index (BMI), (B) weight, (C) estimated plasma volume calculated by Strauss estimation, (D) total body of water, (E) fat-free mass, and (F) extracellular fluid are reported after week 1 and week 12 of dapagliflozin treatment or placebo subtracted from baseline values in patients at cardiovascular risk. *P* values displayed at the top of the figure correspond to between-group comparisons. All other *P* values represent within-group comparisons. A linear mixed-effects model was used to analyze end points, incorporating treatment group, visit, and treatment-by-visit interaction as fixed effects, with a patient-level intercept included as a random effect to account for within-subject correlation. Two-sided significance tests were conducted with $\alpha=0.05$, and nominal *P* values were reported.

Effect of Dapagliflozin on Plasma and Urine Biochemistry

Acute dapagliflozin treatment significantly decreased plasma levels of urate by $46.0 \pm 13.5 \mu\text{mol/L}$ ($P=0.001$)

from baseline and this effect was sustained with chronic treatment ($P=0.01$). Placebo-corrected changes in hemoglobin ($P=0.09$) and hematocrit (0.19), were not significant at 1 week, but did reach significance after 12 weeks of treatment ($P=0.02$ for both). Levels of magnesium

increased significantly by 0.04 ± 0.01 mmol/L after 1 week of dapagliflozin ($P=0.006$), but changes were not sustained. Although no acute change in fasting plasma glucose was observed, 12 weeks of dapagliflozin led to significant reductions by -0.9 ± 0.4 mmol/L ($P=0.04$). Other safety plasma and urine markers are reported in the [Tables S6 and S12](#).

Subgroup Analysis By Diabetes Status

The effects of dapagliflozin on blood pressure, arterial stiffness ([Figure S4](#)), natriuresis, measured GFR, noninvasive cardiac output monitoring, FMD, and safety outcomes did not differ based on diabetes status.

Adverse Events

One participant assigned to the placebo group experienced a serious adverse event and required hospitalization due to heart failure. Of the adverse events of interest, 3 separate mild hypoglycemic episodes were reported, 2 of which occurred in participants randomized to dapagliflozin treatment and 1 in the placebo group. Two separate mild cases of acute kidney injury were reported during the trial, 1 in the dapagliflozin group and 1 in the placebo group. One participant randomized to the placebo group experienced a urinary tract infection that was resolved during the trial. There were no episodes of ketoacidosis or volume depletion events.

DISCUSSION

The present trial systematically explored the effects of SGLT2 inhibition on vascular, cardiac, kidney and neurohormonal variables in a mixed cohort of participants with and without T2D at varying degrees of increased cardiovascular risk. Specifically, vascular stiffness as measured by aortic Alx was reduced over 12 weeks. We also observed acute reductions in measured GFR and acute proximal tubular natriuresis—findings consistent with reductions in glomerular hypertension and hyperfiltration. Systemically, there was evidence of acute and chronic changes in volume status with the use of dapagliflozin. Dapagliflozin elicited early physiological changes relevant to cardiovascular and kidney risk, including a reduction in arterial stiffness suggestive of improved ventricular-vascular coupling, and kidney findings indicative of an intact adaptive response to changes in sodium and volume balance. These findings provide mechanistic support for the potential preventive benefits of SGLT2 inhibition in participants at varying levels of cardiovascular risk in whom evidence of clinical protection is lacking.

The present trial provides a detailed integrative analysis of SGLT2 inhibition in a patient population with and without T2D. Clinical cardiovascular and kidney benefits with SGLT2 inhibitors have been established in patients

regardless of T2D status, specifically in those with CKD or heart failure.⁷ Therefore, the impact of SGLT2 inhibition in this trial population is important due to its consistency with clinical benefits in people with and without T2D.^{14,15,48} However, this trial extends our understanding of how SGLT2 inhibitors may provide protection in a patient population in which we do not currently have clinical trials demonstrating cardiovascular or kidney benefits. Reviewing our cohort, 15 participants without T2D and 13 participants with T2D, together representing 55% of the combined cohort, did not have a strong clinical indication for cardiovascular or kidney protection with an SGLT2 inhibitor based on current trials and guidelines. Among those without T2D were patients with an estimated GFR >45 mL/min per 1.73m^2 , and without albuminuria or heart failure. Similarly, the 13 participants with T2D included individuals with an estimated GFR >45 mL/min per 1.73m^2 , and without albuminuria, heart failure or established ASCVD. The mean estimated 10-year risk of ASCVD in these patients with T2D, based on the American Heart Association's Predicting Risk of Cardiovascular Disease Events score, was 9.5%. Therefore, these participants were mostly at the lower end of the cardiovascular (and kidney disease) risk spectrum. Taken together, the demonstration of cardiorenal effect with SGLT2 inhibition in patients who draw from lower cardiovascular and kidney risk populations in which evidence of cardiovascular and kidney protection is lacking strengthens the argument for large, pragmatic clinical trials or the generation of real-world evidence in this patient population.

At baseline, the aortic Alx for the cohort averaged 19%, which decreased to $\approx 13\%$ after 12 weeks of dapagliflozin treatment, moving closer to, but still above, the normative value of $\approx 10.3\%$ reported in 60- to 69-year-old men.⁴⁹ This reduction of about 6% to 7% may have clinical implications. Supporting this, modest increases in Alx have been linked to worse outcomes: in a meta-analysis of 5648 subjects followed for 45 months, every 10% absolute increase in central Alx was associated with a 32% higher risk of future cardiovascular events and 38% higher risk of all-cause mortality.⁵⁰ Likewise, in a cohort of patients with coronary artery disease, every 10% increase in Alx was associated with a 28% higher risk of major adverse cardiovascular events.⁵¹ In another study, men in the highest tertile of Alx had 1.60-fold higher risk of combined cardiovascular events compared with those in the lowest tertile.⁵² Taken together, these findings suggest that even modest improvements in Alx as observed in our cohort may translate to substantial cardiovascular benefit.

Carotid-femoral PWV, however, remained unchanged. The aortic Alx and carotid-femoral PWV are both generally considered indices of large artery central stiffness that provide complementary information towards patient risk.⁵³ For example, both the aortic Alx and

carotid-femoral PWV are independently associated with adverse events across a range of cardiovascular and kidney disease conditions.^{18,19} In some populations, aortic Alx is predictive of mortality even in the setting of normal PWV.⁵⁴ However, both indices can be experimentally modified independently.^{55,56} While the current work is unable to determine why dapagliflozin selectively lowered aortic Alx and not carotid-femoral PWV, 1 possibility may relate to the greater influence of arteriolar tone on aortic Alx.⁵⁶ However, reductions in Alx were not accompanied by reductions in peripheral resistance and blood pressure in our study, making it less likely that altered vasomotor tone was the primary driver. No significant changes were observed in FMD or glyceryl trinitrate, indicating that improvements in endothelial function or smooth muscle responsiveness are unlikely to account for the selective reduction in Alx. This strengthens the interpretation that changes in Alx may reflect alterations in wave reflection or peripheral arterial tone independent of conduit artery endothelial function. Consistent with this, a meta-analysis of SGLT2 inhibitors demonstrated modest improvements in FMD (standardized effect size 0.18) but no significant effect on PWV,⁵⁷ suggesting that endothelial improvements may accompany but do not necessarily drive changes in central arterial stiffness or wave reflection. Experimental evidence further supports the independent modulation of Alx and carotid-femoral PWV; administration of vasodilators such as nitroglycerin and vasoconstrictors like angiotensin II produces large shifts in Alx with minimal changes in carotid-femoral PWV in healthy subjects, highlighting greater sensitivity of Alx to peripheral vascular tone.⁵⁸ Collectively, these findings suggest that Alx reduction with dapagliflozin may preferentially reflect effects on wave reflections or small artery function rather than changes in large artery stiffness.

Dapagliflozin increased proximal and total natriuresis, as measured by FE_{Li} and FE_{Na} , respectively. This was also accompanied by increases in 24-hour glucose excretion. However, natriuresis was not sustained at 12 weeks, suggesting that adaptive mechanisms may have blunted this effect over time. This attenuation is consistent with prior findings that show the natriuretic response to SGLT2 inhibitors is most pronounced early in therapy—often evident by day 1—and diminishes with continued use following 14 days of treatment.⁵⁸ Mechanistically, this attenuated total natriuresis may be attributed to a series of counter-regulatory adaptations in tubular sodium handling, including reductions in proximal sodium excretion and increases in distal sodium reabsorption.^{59–61} Proteomic studies have further implicated factors such as carbonic anhydrase and uromodulin in mediating increased sodium retention in both the proximal tubule and the thick ascending limb of Henle's loop.⁵⁹ In addition, volume contraction associated with initial natriuresis can activate the RAAS, promoting sodium reabsorption in

the distal nephron.^{62,63} As observed in longer-term studies (eg, 4–6 weeks), sodium excretion and FENa often return to baseline, indicating that the natriuretic effect of SGLT2 inhibition may be transient.^{60,64,65} Although SGLT2 inhibition offers clinically meaningful benefits in the setting of heart failure, it is unclear to what extent, if any, these benefits are mediated by the diuretic effects of SGLT2 inhibitors.⁵⁸ Prior work initially proposed that the natriuretic and diuretic effects of SGLT2 inhibition were the primary mechanisms responsible for clinical benefit, particularly in the setting of heart failure.^{66–68} However, contemporary work has suggested that these mechanisms do not mediate clinical benefit,^{69,70} but serve to restore sodium balance, thereby blunting the initial natriuretic effect despite continued glucosuria. Natriuresis and diuresis appear to characterize early effects of SGLT2 inhibition that subsequently attenuate with time, suggesting activation of alternate pathways that confer clinical benefit. It has also been proposed that a persistent effect of SGLT2 inhibition on proximal tubular natriuresis resets volume homeostasis which may allow individuals to better manage episodes of volume expansion, preventing exacerbations of heart failure in those at risk.

Our results also demonstrate evidence of TGF activation within a cohort with 80% background use of renin-angiotensin blockade and 35% background use of diuretic therapy. In addition to the observed acute proximal tubular natriuresis with dapagliflozin, there was an accompanying acute and chronic dip in measured GFR as well as increases in urine adenosine. SGLT2 inhibition is known to result in an acute and reversible 4 to 6 mL/min per 1.73m² dip in GFR, though the exact hemodynamic mechanism that is responsible remains controversial. Glomerular perfusion is regulated via different feedback mechanisms, including distal sodium delivery to the macula densa. Sodium from the tubular lumen enters the macula densa through $Na^+/K^+/2Cl^-$ cotransporters and stimulates the local generation of ATP or adenosine.⁷¹ By increasing distal sodium delivery, SGLT2 inhibitors are hypothesized to restore TGF and have been demonstrated to reduce calculated intraglomerular pressure.¹⁴ Observed increases in placebo-adjusted urine adenosine with dapagliflozin suggest activation of TGF mechanisms, as early as 1 week after initiation of therapy, results that are consistent with mechanistic studies in a variety of patient populations.^{42,72–74}

Acute increases in natriuresis with dapagliflozin were accompanied by acute changes in volume status. This included in significant acute reduction in extracellular fluid volume and total body water. Although natriuresis was not sustained with dapagliflozin, there was evidence of sustained volume effect with reductions in estimated plasma volume at 12 weeks. As with other findings in this study, volume effects observed in our study are consistent with existing literature. The Empagliflozin in Heart Failure Patients with Reduced Ejection Fraction Trial

(EMPIRE-HF) examined the change in extracellular volume in patients with heart failure randomized to empagliflozin versus placebo for 12 weeks,⁷⁵ and showed that empagliflozin reduced estimated extracellular volume compared with placebo by a modest 0.12 L. Other studies also examined changes in extracellular volume with SGLT2 inhibition using bioimpedance spectroscopy and demonstrated reductions ranging from 0.5 to 1 L that tended to dissipate over time.⁶¹ In contrast with this previous work, plasma volume in the current study was estimated using the Strauss equation, which evaluates changes in hematocrit relative to hemoglobin, both of which increased with dapagliflozin over time in our study.⁴⁵ Analyses of SGLT2 inhibitor outcome trials have identified changes in hematocrit to be most closely associated with improvements in cardiovascular and kidney outcomes, possibly by protection against the development of volume overload.^{76–79} One major limitation of using the Strauss equation to estimate plasma volume in the context of SGLT2 inhibitors is the potential effects of this class of drugs on erythropoietin and reticulocytosis.^{80,81} Regardless, changes in estimated plasma volume, bioimpedance measured extracellular fluid, and body weight observed in this study were all concordant and suggestive of systemic volume reduction, although these changes were not accompanied by sympathetic activation. Also consistent with a systemic volume effect was the demonstration of acute RAAS activation—effects that have been mirrored in previous work.¹⁶

There are limitations to this analysis. First, although acute measured GFR changes were noted, we did not assess renal blood flow in this study. In the absence of renal hemodynamic measurements, we were unable to discern whether changes in postglomerular arteriolar resistance or preglomerular arteriolar resistance contributed to GFR changes. Second, treatment allocation was not stratified by diabetes status, which may limit the ability to draw definitive conclusions about differential treatment effects between participants with and without diabetes. A third limitation is multiple comparisons between groups, which could increase the risk of type 1 errors. Fourth, discordant response observed between aortic Alx and carotid-femoral PWV complicates interpretation, especially given that PWV generally demonstrates greater reproducibility and validity compared with Alx. Finally, despite intentional efforts to recruit female participants, the study population was predominantly male. This limitation reflects a broader challenge, as females are generally underrepresented in clinical trials.⁸²

In conclusion, in individuals at varying levels of cardiovascular risk, dapagliflozin treatment over 12 weeks led to measurable improvements in vascular function, volume status, glycemic control, and renal sodium handling—consistent with mechanisms thought to underlie long-term cardiovascular and kidney protection. Reductions in Alx are suggestive of improved ventricular-vascular coupling with dapagliflozin, which, along with changes in volume

status and restoration of TGF, leading to kidney protection, may reduce the risk of heart failure with preserved ejection fraction in this cohort. These cardiorenal effects may represent early signals relevant to the prevention of cardiovascular complications in this at-risk population. This study suggests that SGLT2 inhibitors may benefit a broader population at varying cardiovascular risk, beyond those currently approved, and can inform future trials aimed at identifying underserved cardiovascular risk subgroups who may also benefit from earlier intervention. Longer-term clinical trials, especially in patients at lower cardiovascular risk from the perspective of primary prevention, are required to assess if these effects translate to improvements in clinical cardio-kidney outcomes.

PERSPECTIVES

This study offers mechanistic insight into how SGLT2 inhibition may confer cardiovascular and kidney protection, even among individuals at lower cardiorenal risk who fall outside current treatment indications. By demonstrating favorable changes in vascular stiffness, glomerular hemodynamics, and systemic volume regulation, the findings support a broader physiological role for SGLT2 inhibitors in modulating risk pathways early in disease progression. These observations raise the possibility that SGLT2 inhibitors could be effective in the primary prevention of cardiovascular and kidney complications, particularly in patients with subclinical risk profiles. Importantly, the concordance between vascular, renal, and volume markers despite the absence of overt clinical disease underscores the potential utility of early intervention in modifying disease trajectories. This integrative approach highlights a need for future trials that move beyond traditional high-risk populations and instead focus on pragmatic strategies to identify and treat individuals earlier in the course of disease. Although the current findings are hypothesis-generating, they suggest that SGLT2 inhibitors could be considered in a broader array of clinical contexts. Further long-term studies and real-world evidence are warranted to determine whether these early physiological effects translate into meaningful reductions in hard cardiovascular and kidney end points in diverse, lower-risk populations.

ARTICLE INFORMATION

Received September 3, 2025; accepted November 17, 2025.

Affiliations

Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, Canada (V.S.S.). Division of Nephrology, Department of Medicine (L.K., Y.L., H.L., J.T., M.N., R.C.Y.L., D.Z.I.C.) and Biostatistics Department (Y.D., L.E.L.), University Health Network, Toronto, Ontario, Canada. Department of Medicine, Temerty Faculty of Medicine (V.S.S., L.K., Y.L., H.L., B.L., J.A.L., B.A.P., D.Z.I.C.), Institute of Health Policy, Management and Evaluation (L.E.L.), and Division of Endocrinology and Metabolism, Department of Medicine (J.A.L., B.A.P.), University of Toronto, Ontario, Canada. Division of Cardiology, University Health Network and Mount Sinai Hospital, Toronto, Ontario, Canada (J.S.F., T.O., T.T.). Department

of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, the Netherlands (J.S., D.J.T., H.J.L.H.). Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada (D.B.). Department of Medicine, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (J.A.L.). Division of Endocrinology and Metabolism, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada (B.A.P.).

Acknowledgments

The authors thank the Castor Electronic Data Capture platform for providing a secure platform for managing study data. The authors thank Eve Technologies Corporation for performing the biomarker assays. The authors thank R. Bekendam, J. Roggevel and J. Nijhoff for performing iohexol and lithium assays. The authors were responsible for all content and editorial decisions. This study was conducted with the support of the Gabor Zellerman Chair in Nephrology Research, University of Toronto, Toronto, Canada.

Sources of Funding

The study was an investigator-initiated study, entirely planned and conducted under the scientific supervision of D.Z.I. Cherney, Y. Lytvyn, B.A. Perkins, and J.A. Lovshin. AstraZeneca Canada Inc supported the trial with a research grant and provided study medications (dapagliflozin and matching placebo). The opinions expressed in this article are those of the authors and do not necessarily represent those of AstraZeneca Canada Inc. The funders had no role in the study design, the analysis or interpretation of the data, or drafting of the manuscript. The funders had no role in the decision to submit this manuscript for publication.

Disclosures

D.Z.I. Cherney has received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, AbbVie, Janssen, Bayer, Prometic, Bristol Myers Squibb, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon and Novo Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring and Novo Nordisk. V.S. Sridhar is supported by the Department of Medicine Eliot Phillipson Clinician Scientist Training Program, a Banting and Best Diabetes center Postdoctoral fellowship at the University of Toronto, and a doctoral award from the Canadian Institutes of Health Research Frederick Banting and Charles Best Canada Graduate Scholarship. V.S. Sridhar has received conference and travel support from Merck Canada and Lexicon Pharmaceuticals. V.S. Sridhar has participated in the advisory board with Novo Nordisk Canada. B.A. Perkins has received speaker honoraria from Abbott, Bayer, Insulet, Dexcom, Medtronic, Novo Nordisk, and Sanofi; has received research grant support from Novo Nordisk and Bank of Montreal; and serves as a consultant for Abbott, Insulet, Dexcom, Sanofi, Vertex, and Nephris. H.J.L. Heerspink receives grant support, lecture fees, and fees for serving on a steering committee, paid to his institution, from AstraZeneca, advisory board fees, paid to his institution, from Astellas, Fresenius, Mundipharma, and Merck, grant support and advisory board fees, paid to his institution, from Boehringer Ingelheim, advisory board fees and lecture fees, paid to his institution, from Mitsubishi-Tanabe, grant support and fees for serving on a steering committee, paid to his institution, from AbbVie, and fees for serving on a steering committee, paid to his institution, from Gilead. J.A. Lovshin has received speaker honoraria or consulting fees from Novo Nordisk, Boehringer Ingelheim, Eli Lilly, and grant support from Merck, Novo Nordisk, and Sanofi. The other authors report no conflicts.

Supplemental Material

Supplemental Methods
Tables S1–S12
Figures S1–S4

REFERENCES

- Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. *J Am Coll Cardiol*. 2020;76:2982–3021. doi: 10.1016/j.jacc.2020.11.010
- Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. *Health Aff (Project Hope)*. 2007;26:38–48. doi: 10.1377/hlthaff.26.1.38
- Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet (London, England)*. 2013;382:339–352. doi: 10.1016/S0140-6736(13)60595-4
- Sud M, Tangri N, Pintilie M, Levey AS, Naimark DM. ESRD and death after heart failure in CKD. *J Am Soc Nephrol*. 2015;26:715–722. doi: 10.1681/ASN.2014030253
- Mark PB, Carrero JJ, Matsushita K, Sang Y, Ballew SH, Grams ME, Coresh J, Surapaneni A, Brunskill NJ, Chalmers J, et al. Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study. *Eur Heart J*. 2023;44:1157–1166. doi: 10.1093/eurheartj/ehac825
- Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, Butler J, Cherney DZI, Claggett BL, Fletcher RA, et al. Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis. *Circulation*. 2024;149:1789–1801. doi: 10.1161/CIRCULATIONAHA.124.069568
- Nuffield Department of Population Health Renal Studies G, Consortium SIM-AC-RT. Impact of diabetes on the effects of sodium glucose cotransporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. *Lancet*. 2022;400:1788–1801. doi: 10.1016/S0140-6736(22)02074-8
- de Boer IH, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, Liew A, Michos ED, Navaneethan SD, Olowu WA, et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. *Kidney Int*. 2020;98:839–848. doi: 10.1016/j.kint.2020.06.024
- Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145:e895–e1032. doi: 10.1161/CIR.0000000000001063
- Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, Herrington WG, Hill G, Inker LA, Kazancioglu R, et al. Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns. *Kidney Int*. 2024;105:684–701. doi: 10.1016/j.kint.2023.10.016
- Fernández-Fernández B, Sarafidis P, Soler MJ, Ortiz A. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. *Clin Kidney J*. 2023;16:1187–1198. doi: 10.1093/ckj/sfad082
- Persson F, Rossing P, Vart P, Chertow GM, Hou FF, Jongs N, McMurray JJV, Correa-Rotter R, Bajaj HS, Stefansson BV, et al; DAPA-CKD Trial Committees and Investigators. Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial. *Diabetes Care*. 2021;44:1894–1897. doi: 10.2337/dc21-0300
- Wheeler DC, Stefansson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, et al; DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. *Lancet Diabetes Endocrinol*. 2021;9:22–31. doi: 10.1016/S2213-8587(20)30369-7
- Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. *Circulation*. 2014;129:587–597. doi: 10.1161/CIRCULATIONAHA.113.005081
- van Bommel EJM, Muskiet MHA, van Baar MJB, Tonneijck L, Smits MM, Emanuel AL, Bozovic A, Danser AHJ, Geurts F, Hoorn EJ, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. *Kidney Int*. 2020;97:202–212. doi: 10.1016/j.kint.2019.09.013
- Lytvyn Y, Kimura K, Peter N, Lai V, Tse J, Cham L, Perkins BA, Soleymanlou N, Cherney DZI. Renal and vascular effects of combined SGLT2 and angiotensin-converting enzyme inhibition. *Circulation*. 2022;146:450–462. doi: 10.1161/CIRCULATIONAHA.122.059150
- Schaub JA, Alakwaa FM, McCown RJ, Naik AS, Nair V, Eddy S, Menon R, Otto EA, Demeke D, Hartman J, et al. SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes. *J Clin Invest*. 2023;133:e164486. doi: 10.1172/JCI164486
- Chirinos JA, Kips JG, Jacobs DR, Brumback L, Duprez DA, Kronmal R, Bluemke DA, Townsend RR, Vermeersch S, Segers P. Arterial wave reflections and incident cardiovascular events and heart failure: MESA (Multiethnic Study of Atherosclerosis). *J Am Coll Cardiol*. 2012;60:2170–2177. doi: 10.1016/j.jacc.2012.07.054

19. Maloberti A, Rebora P, Occhino G, Andreano A, Intravaia RCM, Tognola C, Toscani G, Peraro G, Morelli M, Rognoni M, et al. Carotid-femoral pulse wave velocity progression in hypertensive patients is associated with subsequent cardiovascular outcomes. *J Hypertens*. 2025;43:797–806. doi: 10.1097/HJH.0000000000003973
20. Palombo C, Kozakova M. Arterial stiffness, atherosclerosis and cardiovascular risk: Pathophysiologic mechanisms and emerging clinical indications. *Vascul Pharmacol*. 2016;77:1–7. doi: 10.1016/j.vph.2015.11.083
21. Boutouyrie P, Chowienczyk P, Humphrey JD, Mitchell GF. Arterial stiffness and cardiovascular risk in hypertension. *Circ Res*. 2021;128:864–886. doi: 10.1161/CIRCRESAHA.121.318061
22. Zoungas S, Asmar RP. Arterial stiffness and cardiovascular outcome. *Clin Exp Pharmacol Physiol*. 2007;34:647–651. doi: 10.1111/j.1440-1681.2007.04654.x
23. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. *Nat Rev Endocrinol*. 2012;8:495–502. doi: 10.1038/nrendo.2011.243
24. Skrtic M, Cherney DZ. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. *Curr Opin Nephrol Hypertens*. 2015;24:96–103. doi: 10.1097/MNH.0000000000000084
25. Cherney DZ, Miller JA, Scholey JW, Bradley TJ, Slorach C, Curtis JR, Dekker MG, Nasrallah R, Hebert RL, Sochett EB. The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. *Diabetes*. 2008;57:688–695. doi: 10.2337/db07-1230
26. Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. *J Am Soc Nephrol*. 1999;10:1778–1785. doi: 10.1681/ASN.V1081778
27. Jones SL, Kontessis P, Wiseman M, Dodds R, Boggetti E, Pinto J, Viberi G. Protein intake and blood glucose as modulators of GFR in hyperfiltering diabetic patients. *Kidney Int*. 1992;41:1620–1628. doi: 10.1038/ki.1992.234
28. Lytvyn Y, Har R, Locke A, Lai V, Fong D, Advani A, Perkins BA, Cherney DZ. Renal and Vascular Effects of uric acid lowering in normouricemic patients with uncomplicated type 1 diabetes. *Diabetes*. 2017;66:1939–1949. doi: 10.2337/db17-0168
29. Lytvyn Y, Bjornstad P, Lovshin JA, Boulet G, Farooqi MA, Lai V, Tse J, Cham L, Lovblom LE, Weisman A, et al. Renal hemodynamic function and RAAS activation over the natural history of type 1 diabetes. *Am J Kidney Dis*. 2019;73:786–796. doi: 10.1053/j.ajkd.2018.12.034
30. Burns KD, Lytvyn Y, Mahmud FH, Daneman D, Deda L, Dunger DB, Deanfield J, Dalton RN, Elia Y, Har R, et al. The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetes. *Am J Physiol Renal Physiol*. 2017;312:F335–F342. doi: 10.1152/ajprenal.00438.2016
31. Xiao F, Burns KD. Measurement of angiotensin converting enzyme 2 activity in biological fluid (ACE2). *Hypertens Methods Protoc*. 2017;1527:101–115. doi: 10.1007/978-1-4939-6625-7_8
32. Stevens J, Wessels MA, Roggeveid J, Koster RA, Dekkers CC, van Gelder MK, Gansevoort RT, Heerspink HJ, Touw DJ. UHPLC-MS/MS method for iohexol determination in human EDTA and lithium-heparin plasma, human urine and in goat-and pig EDTA plasma. *Bioanalysis*. 2020;12:981–990. doi: 10.4155/bio-2020-0122
33. Bröchner-Mortensen J. A simple method for the determination of glomerular filtration rate. *Scand J Clin Lab Invest*. 1972;30:271–274. doi: 10.3109/00365517209084290
34. Montanari A, Biggi A, Cabassi A, Pelloni I, Pigazzani F, Pinelli S, Pelà G, Musiari L, Cherney DZ. Renal hemodynamic response to L-arginine in uncomplicated, type 1 diabetes mellitus: the role of buffering anions and tubuloglomerular feedback. *Am J Physiol Renal Physiol*. 2012;303:F648–F658. doi: 10.1152/ajprenal.00149.2012
35. Koomans HA, Boer WH, Dorhout Mees EJ. Evaluation of lithium clearance as a marker of proximal tubule sodium handling. *Kidney Int*. 1989;36:2–12. doi: 10.1038/ki.1989.153
36. Montanari A, Vallisa D, Ragni G, Guerra A, Colla R, Novarini A, Coruzzi P. Abnormal renal responses to calcium entry blockade in normotensive offspring of hypertensive parents. *Hypertension*. 1988;12:498–505. doi: 10.1161/01.hyp.12.5.498
37. Wilkinson IB, McEniery CM, Schillaci G, Boutouyrie P, Segers P, Donald A, Chowienczyk PJ, Society A. ARTERY Society guidelines for validation of non-invasive haemodynamic measurement devices: Part 1, arterial pulse wave velocity. *Artery Res*. 2010;4:34–40.
38. Keren H, Burkhoff D, Squara P. Evaluation of a noninvasive continuous cardiac output monitoring system based on thoracic bioimpedance. *Am J Physiol Heart Circ Physiol*. 2007;293:H583–H589. doi: 10.1152/ajpheart.00195.2007
39. Simpson J, Lopez L, Acar P, Friedberg MK, Khoo NS, Ko HH, Marek J, Marx G, McGhie JS, Meijboom F, et al. Three-dimensional echocardiography in congenital heart disease: an expert consensus document from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2017;30:1–27. doi: 10.1016/j.jecho.2016.08.022
40. Lytvyn Y, Mahmud FH, Daneman D, Deda L, Dunger DB, Deanfield J, Dalton RN, Elia Y, Har R, Bradley TJ, et al. Association between plasma uric acid levels and cardiorenal function in adolescents with type 1 diabetes. *Diabetes Care*. 2016;39:611–616. doi: 10.2337/dc15-2345
41. Har R, Lai V, Cherney D. The effect of sex on endothelial function responses to clamped hyperglycemia in type 1 diabetes. *Hypertens Res*. 2014;37:220–224. doi: 10.1038/hr.2013.136
42. Cherney DZ, Reich HN, Jiang S, Har R, Nasrallah R, Hébert RL, Lai V, Scholey JW, Sochett EB. Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus. *Am J Physiol Regul Integr Comp Physiol*. 2012;303:R710–R718. doi: 10.1152/ajpregu.00286.2012
43. Cherney DZ, Scholey JW, Jiang S, Har R, Lai V, Sochett EB, Reich HN. The effect of direct renin inhibition alone and in combination with ACE inhibition on endothelial function, arterial stiffness, and renal function in type 1 diabetes. *Diabetes Care*. 2012;35:2324–2330. doi: 10.2337/dc12-0773
44. Birzniece V, Khaw CH, Nelson AE, Meinhardt U, Ho KK. A critical evaluation of bioimpedance spectroscopy analysis in estimating body composition during GH treatment: comparison with bromide dilution and dual X-ray absorptiometry. *Eur J Endocrinol*. 2015;172:21–28. doi: 10.1530/EJE-14-0660
45. Strauss MB, Davis RK, Rosenbaum JD, Rossmeisl EC. "Water diuresis" produced during recumbency by the intravenous infusion of isotonic saline solution. *J Clin Invest*. 1951;30:862–868. doi: 10.1172/JCI102501
46. Duarte K, Monnez JM, Albuissou E, Pitt B, Zannad F, Rossignol P. Prognostic value of estimated plasma volume in heart failure. *JACC Heart Fail*. 2015;3:886–893. doi: 10.1016/j.jchf.2015.06.014
47. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. *Cardiovasc Diabetol*. 2014;13:28. doi: 10.1186/1475-2840-13-28
48. Leon-Jimenez D, Sridhar VS, Lopez-Mendoza M, Scholtes RA, Schmieder RE, Cherney DZ, van Raalte DH, Toro-Prieto FJ, Miramontes-Gonzalez JP, van Bommel EJM. Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications. *Clin Kidney J*. 2025;18:sfae370. doi: 10.1093/ckj/sfae370
49. Diaz A, Zocalo Y, Bia D, Wray S, Fischer EC. Reference intervals and percentiles for carotid-femoral pulse wave velocity in a healthy population aged between 9 and 87 years. *J Clin Hypertens*. 2018;20:659–671. doi: 10.1111/jch.13251
50. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. *Eur Heart J*. 2010;31:1865–1871. doi: 10.1093/eurheartj/ehq024
51. Chirinos JA, Zambrano JP, Chakko S, Veerani A, Schob A, Willens HJ, Perez G, Mendez AJ. Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. *Hypertension*. 2005;45:980–985. doi: 10.1161/01.HYP.0000165025.16381.44
52. Janner JH, Godtfredsen NS, Ladelund S, Vestbo J, Prescott E. High aortic augmentation index predicts mortality and cardiovascular events in men from a general population, but not in women. *Eur J Prev Cardiol*. 2013;20:1005–1012. doi: 10.1177/2047487312449588
53. Prado G, Forner MJ, Calaforra O, Vela S, Bea C, Pichler G, de Gracia A, Serna L, Rodilla E, Redon J, et al. Usefulness of arterial stiffness as an integrated marker of cardiovascular risk. *J Clin Hypertens (Greenwich)*. 2025;27:e70038. doi: 10.1111/jch.70038
54. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. *Hypertension*. 2001;38:434–438. doi: 10.1161/01.hyp.38.3.434
55. Gordin D, Rönnback M, Forsblom C, Heikkilä O, Saraheimo M, Groop PH. Acute hyperglycaemia rapidly increases arterial stiffness in young patients with type 1 diabetes. *Diabetologia*. 2007;50:1808–1814. doi: 10.1007/s00125-007-0730-0
56. Kelly RP, Millasseau SC, Ritter JM, Chowienczyk PJ. Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men. *Hypertension*. 2001;37:1429–1433. doi: 10.1161/01.hyp.37.6.1429

57. Wei R, Wang W, Pan Q, Guo L. Effects of SGLT-2 inhibitors on vascular endothelial function and arterial stiffness in subjects with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Front Endocrinol*. 2022;13:826604. doi: 10.3389/fendo.2022.826604
58. Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. *Circulation*. 2020;142:1028–1039. doi: 10.1161/CIRCULATIONAHA.120.045691
59. Zannad F, Ferreira JP, Butler J, Filippatos G, Januzzi JL, Sumin M, Zwick M, Saadati M, Pocock SJ, Sattar N, et al. Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme. *Eur Heart J*. 2022;43:4991–5002. doi: 10.1093/eurheartj/ehac495
60. Rao VS, Ivey-Miranda JB, Cox ZL, Moreno-Villagomez J, Maulion C, Bellumkonda L, Chang J, Field MP, Wiederin DR, Butler J, et al. Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects. *J Am Soc Nephrol*. 2024;35:189–201. doi: 10.1681/ASN.0000000000000269
61. Nardone M, Sridhar VS, Yau K, Odutayo A, Cherney DZI. Proximal versus distal diuretics in congestive heart failure. *Nephrol Dial Transplant*. 2024;39:1392–1403. doi: 10.1093/ndt/gfae058
62. Schork A, Saynisch J, Vosseler A, Jaghutriz BA, Heyne N, Peter A, Häring HU, Stefan N, Fritsche A, Artunc F. Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. *Cardiovasc*. 2019;18:1–12. doi: 10.1186/s12933-019-0852-y
63. Masuda T, Muto S, Fukuda K, Watanabe M, Ohara K, Koepsell H, Vallon V, Nagata D. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume. *Physiol Rep*. 2020;8:e14360. doi: 10.14814/phy2.14360
64. Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC. Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial. *Circulation*. 2020;142:1713–1724. doi: 10.1161/CIRCULATIONAHA.120.048739
65. Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, Bramlage P, Nöh L, Schiffer M, et al. The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial. *Clin Res Cardiol*. 2023;112:134–144. doi: 10.1007/s00392-022-02119-7
66. Cherney DZ, Kanbay M, Lovshin JA. Renal physiology of glucose handling and therapeutic implications. *Nephrol Dial Transplant*. 2020;35:i3–i12. doi: 10.1093/ndt/gfz230
67. Thomas MC, Cherney DZ. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. *Diabetologia*. 2018;61:2098–2107.
68. Takeuchi T, Dohi K, Omori T, Moriwaki K, Sato Y, Nakamori S, Fujimoto N, Fujii E, Yamada N, Ito M. Diuretic effects of sodium–glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure. *Int J Cardiol*. 2015;201:1–3. doi: 10.1016/j.ijcard.2015.07.072
69. Scholtes RA, Muskiet MH, van Baar MJ, Hesp AC, Greasley PJ, Karlsson C, Hammarstedt A, Arya N, van Raalte DH, Heerspink HJ. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. *Diabetes Care*. 2021;44:440–447. doi: 10.2337/dc20-2604
70. Marton A, Saffari SE, Rauh M, Sun RN, Nagel AM, Linz P, Lim TT, Takase-Minegishi K, Pajarillaga A, Saw S, et al. Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure. *J Am Coll Cardiol*. 2024;83:1386–1398. doi: 10.1016/j.jacc.2024.02.020
71. Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH, Joles JA. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. *J Am Soc Nephrol*. 2017;28:1023–1039. doi: 10.1681/ASN.2016060666
72. Thorup C, Persson AE. Inhibition of locally produced nitric oxide resets tubuloglomerular feedback mechanism. *Am J Physiol*. 1994;267:F606–F611. doi: 10.1152/ajprenal.1994.267.4.F606
73. Turkstra E, Braam B, Koomans HA. Nitric oxide release as an essential mitigating step in tubuloglomerular feedback: observations during intrarenal nitric oxide clamp. *J Am Soc Nephrol*. 1998;9:1596–1603. doi: 10.1681/ASN.V991596
74. Rajasekaran H, Lytyn Y, Bozovic A, Lovshin JA, Diamandis E, Cattran D, Husain M, Perkins BA, Advani A, Reich HN, et al. Urinary adenosine excretion in type 1 diabetes. *Am J Physiol Renal Physiol*. 2017;313:F184–F191. doi: 10.1152/ajprenal.00043.2017
75. Jensen J, Omar M, Kistorp C, Tuxen C, Gustafsson I, Kober L, Gustafsson F, Faber J, Malik ME, Fosbol EL, et al. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol*. 2021;9:106–116. doi: 10.1016/S2213-8587(20)30382-X
76. Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. *Diabetes Care*. 2018;41:356–363. doi: 10.2337/dc17-1096
77. Li J, Neal B, Perkovic V, de Zeeuw D, Neuen BL, Arnott C, Simpson R, Oh R, Mahaffey KW, Heerspink HJL. Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. *Kidney Int*. 2020;98:769–777. doi: 10.1016/j.kint.2020.04.051
78. Li J, Woodward M, Perkovic V, Figtree GA, Heerspink HJL, Mahaffey KW, de Zeeuw D, Vercruysse F, Shaw W, Matthews DR, et al. Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes. *JACC Heart Fail*. 2020;8:57–66. doi: 10.1016/j.jchf.2019.08.004
79. Segar MW, Kolkailah AA, Frederich R, Pong A, Cannon CP, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley RE, Liu CC, et al. Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. *Diabetes Obes Metab*. 2022;24:1829–1839. doi: 10.1111/dom.14769
80. Packer M. Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium–glucose cotransporter 2 inhibitors. *Eur Heart J*. 2023;44:5027–5035. doi: 10.1093/eurheartj/ehad235
81. Lawler PR, Liu H, Frankfurter C, Lovblom LE, Lytyn Y, Burger D, Burns KD, Brinc D, Cherney DZI. Changes in cardiovascular biomarkers associated with the sodium–glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin in patients with chronic kidney disease and type 2 diabetes. *Diabetes Care*. 2021;44:e45–e47. doi: 10.2337/dc20-2265
82. Katz-Greenberg G, Shah S. Sex and gender differences in kidney transplantation. *Semin Nephrol*. 2022;42:219–229. doi: 10.1016/j.semnephrol.2022.04.011